Lantheus (NASDAQ:LNTH) Downgraded to Sell at Zacks Investment Research

Lantheus (NASDAQ:LNTHGet Rating) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “

A number of other equities research analysts also recently weighed in on LNTH. SVB Leerink raised their price target on Lantheus from $34.00 to $75.00 and gave the stock an “outperform” rating in a research note on Thursday, February 24th. StockNews.com started coverage on Lantheus in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, Truist Financial started coverage on Lantheus in a research note on Tuesday, April 12th. They issued a “buy” rating and a $77.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $51.00.

Shares of NASDAQ LNTH opened at $57.99 on Wednesday. Lantheus has a one year low of $19.30 and a one year high of $64.14. The firm has a market capitalization of $3.95 billion, a PE ratio of -55.23, a PEG ratio of 0.94 and a beta of 0.95. The company has a current ratio of 2.61, a quick ratio of 2.22 and a debt-to-equity ratio of 0.35. The business has a 50-day moving average price of $52.41 and a two-hundred day moving average price of $35.78.

Lantheus (NASDAQ:LNTHGet Rating) last posted its quarterly earnings results on Thursday, February 24th. The medical equipment provider reported $0.25 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.08. Lantheus had a positive return on equity of 6.80% and a negative net margin of 16.76%. The company had revenue of $129.60 million during the quarter, compared to the consensus estimate of $111.77 million. During the same period last year, the business earned $0.07 EPS. The business’s quarterly revenue was up 37.7% on a year-over-year basis. Research analysts anticipate that Lantheus will post 1.86 EPS for the current year.

In other news, SVP Carol Walker sold 1,536 shares of Lantheus stock in a transaction that occurred on Friday, March 4th. The stock was sold at an average price of $49.98, for a total transaction of $76,769.28. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Andrea Sabens sold 2,409 shares of the business’s stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $48.04, for a total value of $115,728.36. The disclosure for this sale can be found here. Insiders have sold a total of 111,618 shares of company stock worth $5,596,663 in the last three months. 1.60% of the stock is owned by insiders.

A number of hedge funds have recently made changes to their positions in the stock. Maryland State Retirement & Pension System boosted its stake in Lantheus by 1.5% in the 4th quarter. Maryland State Retirement & Pension System now owns 26,986 shares of the medical equipment provider’s stock valued at $780,000 after buying an additional 386 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Lantheus by 9.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,649 shares of the medical equipment provider’s stock valued at $534,000 after purchasing an additional 814 shares during the last quarter. O Shaughnessy Asset Management LLC raised its position in Lantheus by 20.7% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 5,056 shares of the medical equipment provider’s stock valued at $130,000 after purchasing an additional 866 shares during the last quarter. Diversified Trust Co raised its position in Lantheus by 7.3% in the 4th quarter. Diversified Trust Co now owns 14,011 shares of the medical equipment provider’s stock valued at $405,000 after purchasing an additional 955 shares during the last quarter. Finally, Advisor Group Holdings Inc. raised its position in Lantheus by 6.2% in the 4th quarter. Advisor Group Holdings Inc. now owns 17,576 shares of the medical equipment provider’s stock valued at $507,000 after purchasing an additional 1,031 shares during the last quarter. 95.27% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Recommended Stories

Get a free copy of the Zacks research report on Lantheus (LNTH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.